COVID-19 Vaccine’s Human Trials Show Positive Results

Moderna, an American biotech company, is testing a COVID-19 vaccine called “mRNA-1273.” And from the phase 1 study, the interim clinical data has shown to be positive.

Bloomberg reports that the preliminary test of the vaccine in healthy volunteers was safe and well-tolerated. The results are just from the first study designed to look into the safety of the vaccine in human volunteers.

The trial is under the monitor of the US government. Moderna plans to have wider testing. The company’s vaccine is another effort in coming up with a treatment for the contagious virus that caused the pandemic. Reuters reported that there is a 26% increase in Moderna shares before the opening of the market in New York.

They won the “fast track” label from the US health agency to accelerate the regulatory review. The company expects that by July, they will initiate a larger late-stage trial.

Scientists are trying to study what level of antibodies will protect the human body against the virus and the duration of that protection.

According to Moderna, the vaccine seemed to show a dose-response, which means that compared to people who got a lower dose of volunteers receiving 100 mcg dose released more antibodies. The data is from eight participants who join the 45-subject safety trial that started in March.

The vaccine of Moderna is one of over 100 vaccines that are being developed to counter the novel coronavirus that killed more than 328,000 people and infected over 5,00,0000.

Blood samples of eight patients who received the Moderna’s vaccine showed to have similar antibody levels to those who have already recovered from the disease, which is a very positive sign.

Most of the volunteers showed typical vaccine reactions while three others who received a high dose suffered from more severe side effects. That dose won’t be reused again. One person who got a middle dose also had more severe side effects. Redness appeared around the injection site.

Side effects included fever, fatigue, headache, and muscle pain. But all resolved within a day.

Moderna Chief Executive Officer said that the company was looking to scale up manufacturing to maximize the number of vaccines produced. The company, Switzerland-based drugmaker Lonza Group AG, and the U.S. government have signed deals to produce the vaccine.

At the moment, there aren’t approved vaccines or treatments for COVID-19. Experts predict that it could take from 12 to 18 months for a safe and effective vaccine to be developed.

>>> Blood Of COVID-19 Patients On Sale For As Much As Rs. 11,00,000 As Vaccine